Alterity therapeutics ltd - adr
ATHE AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has been awarded the top rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.
ATHE Current Performance
-5.08%
Alterity therapeutics ltd - adr
3.24%
Avg of Sector
0.80%
S&P500
Top 10 High Relevance to ATHE
| Symbol | Value | Trend | Swing Trading | Whale Interest | Dividend | Market Cap | Add to Watchlist |
|---|---|---|---|---|---|---|---|
TIL Instil bio inc | - | 4 | 2 | 2 | 1 | 41.1M | |
EYPT Eyepoint pharmaceuticals inc | 2 | 4 | 2 | 3 | 1 | 747.9M | |
LSDI Lucy scientific discovery inc | - | 1 | 2 | 1 | 1 | 5.8M | |
SYRS Syros pharmaceuticals inc | 4 | 4 | 2 | 2 | 1 | 98.2M | |
PTE Polarityte inc | - | 3 | 2 | - | 1 | 1.8M |
- TIL Instil bio incValue -Trend 4Swing Trading 2Whale Interest 2Dividend 1Market Cap 41.1MSee more
ATHE Profile
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.